AR087853A1 - Inhibidores del canal de potasio medular externo renal - Google Patents

Inhibidores del canal de potasio medular externo renal

Info

Publication number
AR087853A1
AR087853A1 ARP120103364A ARP120103364A AR087853A1 AR 087853 A1 AR087853 A1 AR 087853A1 AR P120103364 A ARP120103364 A AR P120103364A AR P120103364 A ARP120103364 A AR P120103364A AR 087853 A1 AR087853 A1 AR 087853A1
Authority
AR
Argentina
Prior art keywords
alkyl
carbon atoms
ring
cycloalkyl
attached
Prior art date
Application number
ARP120103364A
Other languages
English (en)
Original Assignee
Merck Sharp & Dohme
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Sharp & Dohme filed Critical Merck Sharp & Dohme
Publication of AR087853A1 publication Critical patent/AR087853A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/12Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/48Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/26Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms
    • C07D211/28Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by nitrogen atoms to which a second hetero atom is attached
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40Oxygen atoms
    • C07D211/44Oxygen atoms attached in position 4
    • C07D211/48Oxygen atoms attached in position 4 having an acyclic carbon atom attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D211/00Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08Bridged systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pulmonology (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente se refiere a los compuestos que tienen la fórmula estructural (1) y a las sales farmacéuticamente aceptables de los mismos que son inhibidores del canal (Kir1,1) de Potasio Medular Externo Renal (ROMK). Los compuestos de fórmula (1) actúan como diuréticos y natriuréticos y por lo tanto son útiles para la terapia y la profilaxis de los trastornos que resultan de una retención excesiva de sal y de agua, que incluye las enfermedades cardiovasculares tales como la hipertensión y el fallo cardíaco crónico y agudo. Reivindicación 1: Un compuesto que tiene la fórmula (1) estructural, o una sal farmacéuticamente aceptable del mismo, en la que: B¹-ZB- es B¹-CHR¹CH₂-, B¹-CHR¹C(O)-, B¹-C(O)-, B¹-CHR¹CH₂C(O)-, B¹-OCH₂C(O)- o B¹-CH(CH₂OH)-; ZA-A¹ es -CHR²¹CR²R²²-A¹, -CH=CR²-A¹, -CºC-A¹, -S-A¹, -CH₂O-A¹, -C(O)CHR²-A¹, -O-A¹, -NHCHR²-A¹, -CH₂N(CH₃)CH₂CH(OH)-A¹, -CH₂N(CH₃)CH(CH₂OH)-A¹, -CH₂N(CH₃)-A¹, -CH₂S-A¹, -CH₂O-A¹, CH₂S(O)-A¹, -CH₂S(O₂)-A¹ o -NH-A¹; A¹ es un compuesto seleccionado del grupo de formulas (2); B¹ es un compuesto del grupo de formulas (3); X es O ó S; R¹ es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, CF₃, -OH, F, -CH₂OH, -C(O)OH, -C(O)O-alquilo C₁₋₆ o R¹ se puede unir a R¹³ᵇ mediante 2 - 3 átomos de carbono ó 1 - 2 átomos de carbono y un heteroátomo para formar un anillo; R² es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, CF₃, -OH, F, -CH₂OH, -C(O)OH, -C(O)O-alquilo C₁₋₆ ó R² se puede unir a R¹³ᵃ mediante 2 - 3 átomos de carbono ó 1 - 2 átomos de carbono y un heteroátomo para formar un anillo; R⁴ es H, -OH, F, -O-alquilo C₁₋₆ ó alquilo C₁₋₆ o se puede unir a R⁵ mediante un enlace o mediante 1 - 4 átomos de carbono, para formar un anillo; R⁵ es H, -OH, F, -O-alquilo C₁₋₆ o alquilo C₁₋₆ o se puede unir a R⁴ mediante un enlace o mediante 1 - 4 átomos de carbono para formar un anillo; R⁶ es -H, alquilo C₁₋₆, -C(O)O-alquilo C₁₋₆, -OH, halógeno, -OC(O)alquilo C₁₋₆, -CH₂OH, -CHF₂, -N(alquilo C₁₋₆)₂, -C₆H₅, -CF₃ o un anillo heteroarilo de 5 ó 6 miembros con 1, 2, 3 ó 4 heteroátomos; R¹³ᵃ es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, -halógeno, CF₃, -CH₂OH, CO₂R¹⁶ᵃ, -OR¹⁶ᵃ, -SR¹⁶ᵃ, -CN, -arilo, -heterociclo, -NR¹⁶ᵃR¹⁸ᵃ ó R¹³ᵃ se puede unir a R² mediante 2 - 3 átomos de carbono ó 1 - 2 átomos de carbono y un heteroátomo para formar un anillo ó R¹³ᵃ se puede unir a R¹⁴ᵃ mediante 3 - 4 átomos de carbono ó 2 - 3 átomos de carbono y un heteroátomo para formar un anillo; R¹³ᵇ es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, -halógeno, CF₃, -CH₂OH, CO₂R¹⁶ᵇ, -OR¹⁶ᵇ, -SR¹⁶ᵇ, -CN, -arilo, -heterociclo, -NR¹⁶ᵇR¹⁸ᵇ o R¹³ᵇ se puede unir a R¹ mediante 2 - 3 átomos de carbono ó 1 - 2 átomos de carbono y un heteroátomo para formar un anillo ó R¹³ᵇ se puede unir a R¹⁴ᵇ mediante 3 - 4 átomos de carbono ó 2 - 3 átomos de carbono y un heteroátomo para formar un anillo; R¹⁴ᵃ es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, -halógeno, CF₃, -CH₂OH, CO₂R¹⁷ᵃ, -OR¹⁷ᵃ, -SR¹⁷ᵃ, CN, -arilo, -heterociclo ó R¹⁴ᵃ se puede unir a R¹³ᵃ mediante 3 - 4 átomos de carbono ó 2 - 3 átomos de carbono y un heteroátomo para formar un anillo; R¹⁴ᵇ es -H, alquilo C₁₋₆, cicloalquilo C₃₋₆, -halógeno, CF₃, -CH₂OH, -CO₂R¹⁷ᵇ, -OR¹⁷ᵇ, -SR¹⁷ᵇ, -CN, -arilo, -heterociclo ó R¹⁴ᵇ se puede unir a R¹³ᵇ mediante 3 - 4 átomos de carbono ó 2 - 3 átomos de carbono y un heteroátomo para formar un anillo; R¹⁵ᵃ es -H, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, alquilo -O-C₁₋₆ ó -CF₃; R¹⁵ᵇ es -H, halógeno, alquilo C₁₋₆, cicloalquilo C₃₋₆, alquilo -O-C₁₋₆ ó -CF₃; R¹⁶ᵃ, R¹⁶ᵇ, R¹⁷ᵃ, R¹⁷ᵇ, R¹⁸ᵃ y R¹⁸ᵇ son independientemente -H, alquilo C₁₋₆, cicloalquilo C₃₋₆; R¹⁹ y R²⁰ son H o se pueden unir mediante un enlace ó 1 - 2 átomos de carbono para formar un anillo de 4 - 5 miembros; y R²¹ y R²² son H o, junto con un átomo de carbono al que se unen, forman un cicloalquilo C₃₋₆.
ARP120103364A 2011-09-16 2012-09-13 Inhibidores del canal de potasio medular externo renal AR087853A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201161535589P 2011-09-16 2011-09-16

Publications (1)

Publication Number Publication Date
AR087853A1 true AR087853A1 (es) 2014-04-23

Family

ID=47883628

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP120103364A AR087853A1 (es) 2011-09-16 2012-09-13 Inhibidores del canal de potasio medular externo renal

Country Status (5)

Country Link
US (1) US9527830B2 (es)
EP (1) EP2755656B1 (es)
AR (1) AR087853A1 (es)
TW (1) TW201317213A (es)
WO (1) WO2013039802A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) * 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2014110401A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) * 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
US9270201B1 (en) 2012-10-25 2016-02-23 mPower Solar Inc. Solar inverter
EP2925322B1 (en) * 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9573961B2 (en) 2012-12-19 2017-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014126944A2 (en) 2013-02-18 2014-08-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014150132A1 (en) 2013-03-15 2014-09-25 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9751881B2 (en) 2013-07-31 2017-09-05 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP3063142B1 (en) * 2013-10-31 2019-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
CN104017021B (zh) * 2014-06-10 2016-07-20 天津师范大学 3-腈基-2,4-二卤苯基膦酸酯及其制备方法与应用
WO2016008064A1 (en) 2014-07-14 2016-01-21 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016060941A1 (en) * 2014-10-14 2016-04-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065582A1 (en) * 2014-10-30 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US20170275292A1 (en) * 2014-10-31 2017-09-28 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016065602A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
WO2016065603A1 (en) 2014-10-31 2016-05-06 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2694899C9 (ru) 2014-12-08 2019-08-28 Цзянсу Хэнжуй Медсин Ко., Лтд. Производные пиридинкарбоксамида, способ их получения и их фармацевтическое применение
EP3233799B1 (en) 2014-12-19 2021-05-19 The Broad Institute, Inc. Dopamine d2 receptor ligands
US10633336B2 (en) 2014-12-19 2020-04-28 The Broad Institute, Inc. Dopamine D2 receptor ligands
EP3250204B1 (en) 2015-01-29 2019-10-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2016127358A1 (en) 2015-02-12 2016-08-18 Merck Sharp & Dohme Corp. Inhibitors of renal outer medullary potassium channel
CN107188875B (zh) * 2016-03-15 2020-11-10 联化科技股份有限公司 一种取代苯酞类化合物的制备方法及其中间体
JP6905993B2 (ja) * 2016-04-20 2021-07-21 ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company 置換された二環式ヘテロ環化合物
CN110139862B (zh) 2016-11-03 2024-01-16 百时美施贵宝公司 可用作romk通道抑制剂的经取代的二环杂环衍生物
CA3065309A1 (en) 2017-06-01 2018-12-06 Bristol-Myers Squibb Company Substituted nitrogen containing compounds
WO2019008115A1 (en) 2017-07-07 2019-01-10 Syngenta Participations Ag HETEROCYCLIC DERIVATIVES HAVING PESTICIDE ACTIVITY HAVING SUBSTITUENTS CONTAINING SULFUR
JP2022534426A (ja) 2019-05-31 2022-07-29 イケナ オンコロジー, インコーポレイテッド Tead阻害剤およびその使用
US11458149B1 (en) 2019-05-31 2022-10-04 Ikena Oncology, Inc. TEAD inhibitors and uses thereof
WO2021105115A1 (en) 2019-11-28 2021-06-03 Bayer Aktiengesellschaft Substituted aminoquinolones as dgkalpha inhibitors for immune activation
CN112675719B (zh) * 2020-12-02 2022-06-17 东莞市逸轩环保科技有限公司 一种耐高温改性滤膜及其制备工艺

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2988551A (en) 1954-07-30 1961-06-13 Union Chimique Belge Sa Piperazine derivatives
GB949088A (en) 1961-06-26 1964-02-12 Lepetit Spa Diazabicyclo-octane derivatives
US3435002A (en) 1967-05-15 1969-03-25 Gen Electric Polyamide acid resins and polyimides therefrom
GB1575310A (en) 1976-11-16 1980-09-17 Anphar Sa Piperidine derivatives
FR2522325B1 (fr) 1982-02-26 1985-08-09 Delalande Sa Nouveaux derives aryliques de la piperazine, de l'homopiperazine et de n,n'-dialkyl diamino-1,2 ethane, leur procede de preparation et leur application en therapeutique
NL8202636A (nl) 1982-06-29 1984-01-16 Gist Brocades Nv Piperazinederivaten, werkwijzen ter bereiding daarvan en farmaceutische preparaten die deze verbindingen bevatten.
US5145885A (en) 1983-08-15 1992-09-08 Ciba-Geigy Corporation Photopolymerizable compositions containing aminoaryl ketone photoinitiators
EP0138754B1 (de) 1983-08-15 1988-05-25 Ciba-Geigy Ag Photohärtbare Gemische
US4579863A (en) 1983-12-06 1986-04-01 Warner-Lambert Company Substituted trans-1,2-diaminocyclohexyl amide compounds
US4661607A (en) 1984-09-21 1987-04-28 Chugai Seiyaku Kabushiki Kaisha Furoxanthone derivatives useful as diuretics
GB8603120D0 (en) 1986-02-07 1986-03-12 Pfizer Ltd Anti-dysrhythmia agents
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
FR2673182A1 (fr) 1991-02-22 1992-08-28 Univ Caen Piperazines n,n'-disubstituees, leur procede de preparation et leur application en therapeutique.
KR100299734B1 (ko) 1993-07-28 2002-01-09 모리타 다카카즈 1,4-(디페닐알킬)피페라진유도체
US5614526A (en) 1995-06-09 1997-03-25 Hoffmann-La Roche Inc. Use of phenoxy-piperzine derivatives
DE69709647T2 (de) 1996-05-20 2002-11-07 Teijin Ltd Cyclischer diarylalkyl diaminederivate als antogoniste von chemokinerezeptoren
DE19637237A1 (de) 1996-09-13 1998-03-19 Merck Patent Gmbh Piperazin-Derivate
JPH10203986A (ja) 1997-01-22 1998-08-04 Mitsubishi Chem Corp 眼疾患用薬剤
WO2000051611A1 (en) 1999-03-03 2000-09-08 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
EP1094063A1 (en) 1999-10-18 2001-04-25 Applied Research Systems ARS Holding N.V. 9-(Piperazinylalkyl)carbazoles as Bax-modulators
WO2002000631A2 (en) 2000-06-29 2002-01-03 Fujisawa Pharmaceutical Co., Ltd. Benzhydryl derivatives
US6352158B1 (en) 2000-07-06 2002-03-05 Warner Lambert Company Unit dose blister package with keyhole assisted opening feature
US6693099B2 (en) 2000-10-17 2004-02-17 The Procter & Gamble Company Substituted piperazine compounds optionally containing a quinolyl moiety for treating multidrug resistance
GB0031088D0 (en) 2000-12-20 2001-01-31 Smithkline Beecham Plc Medicaments
US6956046B2 (en) * 2001-05-25 2005-10-18 Mochida Pharmaceutical Co., Ltd. 4-hydroxypiperidine derivatives having analgesic activity
CN1172919C (zh) 2002-06-03 2004-10-27 上海医药工业研究院 芳烷醇哌嗪衍生物及其在制备抗抑郁症药物中的应用
GB0220214D0 (en) 2002-08-30 2002-10-09 Novo Pharmaceuticals De Ltd Compounds and their use
US20040204404A1 (en) 2002-09-30 2004-10-14 Robert Zelle Human N-type calcium channel blockers
AU2003275632A1 (en) 2002-10-25 2004-05-13 Mitsubishi Pharma Corporation N-oxide compounds
WO2004046110A1 (ja) 2002-11-15 2004-06-03 Yamanouchi Pharmaceutical Co., Ltd. メラニン凝集ホルモン受容体拮抗剤
ES2285444T3 (es) 2003-04-03 2007-11-16 Merck Patent Gmbh Derivados de la 1-(fenil)-amida)-2-(fenil)-amida) del acido pirazolidin-1,2-dicarboxilico como inhibidores del factor de coagulacion xa para el tratamiento de la trombosis.
MXPA05010444A (es) 2003-04-03 2005-11-04 Merck Patent Gmbh Compuestos de carbonilo.
DE10329457A1 (de) 2003-04-03 2005-01-20 Merck Patent Gmbh Ethinylprolinderivate
AU2004246766B2 (en) 2003-06-18 2009-09-17 Merck Patent Gmbh Pyrrolidin-1, 2- dicarboxylic acid- 1- [(4- ethinyl- phenyl) - amid]- 2- [(phenyl)- amid] derivative as inhibitors of coagulation factor Xa and VIIa for the treatment of thrombosis
EP1653960A4 (en) 2003-08-13 2008-11-26 Amgen Inc MELANIN CONCENTRATION HORMONE RECEPTOR ANTAGONIST
CN1897950A (zh) 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
GB0325956D0 (en) 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
EP1814551A2 (en) 2004-09-20 2007-08-08 Xenon Pharmaceuticals Inc. Pyridazine derivatives for inhibiting human stearoyl-coa-desaturase
DE102004045796A1 (de) 2004-09-22 2006-03-23 Merck Patent Gmbh Arzneimittel enthaltend Carbonylverbindungen sowie deren Verwendung
DE102004047254A1 (de) 2004-09-29 2006-04-13 Merck Patent Gmbh Carbonylverbindungen
WO2006098342A1 (en) 2005-03-16 2006-09-21 Astellas Pharma Inc. Piperazinyl compounds
GB0510139D0 (en) 2005-05-18 2005-06-22 Addex Pharmaceuticals Sa Novel compounds B1
US7754724B2 (en) 2005-06-30 2010-07-13 Dow Agrosciences Llc N-substituted piperazines
US8071602B2 (en) * 2005-08-09 2011-12-06 M's Science Corporation Piperidine and piperazine derivatives
EP2407453A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. PGD2 receptor antagonist
MX2008008337A (es) 2005-12-21 2008-09-03 Schering Corp Fenoxipiperidinas y sus analogos utiles como antagonistas de histamina h3.
US8309545B2 (en) * 2006-10-04 2012-11-13 Bionomics Limited Benzofuran potassium channel blockers and uses thereof
WO2008147864A2 (en) 2007-05-22 2008-12-04 Xenon Pharmaceuticals Inc. Methods of using piperazine compounds in treating sodium channel-mediated diseases or conditions
US8507539B2 (en) 2008-06-13 2013-08-13 Bionomics Limited Potassium channel blockers and uses thereof
US8673920B2 (en) 2009-05-06 2014-03-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632465B1 (en) 2010-10-27 2015-12-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2632464B1 (en) 2010-10-29 2015-04-29 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
RU2014110401A (ru) 2011-08-19 2015-09-27 Мерк Шарп И Доум Корп. Ингибиторы внешнего медуллярного калиевого канала почек
EP2771005B1 (en) 2011-10-25 2016-05-18 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013062900A1 (en) 2011-10-25 2013-05-02 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
US9493474B2 (en) 2011-10-31 2016-11-15 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2773206B1 (en) 2011-10-31 2018-02-21 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2013066714A1 (en) 2011-10-31 2013-05-10 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
EP2790511B1 (en) 2011-12-16 2016-09-14 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
WO2014015495A1 (en) 2012-07-26 2014-01-30 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel
AR092031A1 (es) 2012-07-26 2015-03-18 Merck Sharp & Dohme Inhibidores del canal de potasio medular externo renal
EP2925322B1 (en) * 2012-11-29 2018-10-24 Merck Sharp & Dohme Corp. Inhibitors of the renal outer medullary potassium channel

Also Published As

Publication number Publication date
US20140235628A1 (en) 2014-08-21
EP2755656A4 (en) 2015-02-25
EP2755656B1 (en) 2016-09-07
TW201317213A (zh) 2013-05-01
WO2013039802A1 (en) 2013-03-21
US9527830B2 (en) 2016-12-27
EP2755656A1 (en) 2014-07-23

Similar Documents

Publication Publication Date Title
AR087853A1 (es) Inhibidores del canal de potasio medular externo renal
AR108101A1 (es) Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
AR085958A1 (es) 8-etil-6-(aril)pirido[2,3-d]pirimidin-7(8h)-onas para el tratamiento de trastornos del cns y cancer
AR100244A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll 7
AR102306A1 (es) Esteroides neuroactivos útiles en el tratamiento de enfermedades del snc
AR091431A1 (es) Compuestos de acido dimetil-benzoico
AR094263A1 (es) Compuestos moduladores selectivos de proteinquinasas
EA201690989A1 (ru) Ингибиторы syk
AR095326A1 (es) Heterociclos tricíclicos como inhibidores de la proteína bet
AR086829A1 (es) Compuestos heterociclicos fusionados como moduladores del canal ionico
AR094378A1 (es) Derivados de pirimidona y su uso en el tratamiento, mejora o prevención de una enfermedad viral
AR094918A1 (es) Compuestos de tetrahidropirrolotiazina como inhibidores de bace
CO6460758A2 (es) Inhibidores del canal de potasio medular externo renal
CU20150084A7 (es) Derivados del ácido 4-((1,1) bisfenil -4-il)-3-(3-fosfonopropanamido)butanoico,activo como inhibidores de nep(endopeptidasa neutral)
AR108102A1 (es) Compuestos agonistas de gpr119 y método para tratar enfermedades y afecciones mediado a través de gpr119
AR097963A1 (es) Antagonistas de receptor ep3 de prostaglandina
AR097199A1 (es) Inhibidores de rorc2 y sus métodos de uso
AR112831A1 (es) Terapia de combinación usando un antagonista del receptor 2 de quimiocina (ccr2) y un inhibidor de pd-1 / pd-l1
AR104306A1 (es) Tetralinas de ácido 3-espiro-7-hidroxámico como inhibidores de hdac
AR102427A1 (es) Derivados de carbazol inhibidores de quinasas
WO2014153203A3 (en) Alkyl-amine harmine derivatives for promoting bone growth
AR094852A1 (es) Oestra-1,3,5(10),16-tetraeno-3-carboxamidas
BR112017012146A2 (pt) derivado de di-hidroindolizinona
AR092749A1 (es) Compuestos farmaceuticos

Legal Events

Date Code Title Description
FA Abandonment or withdrawal